The week in pharma: action, reaction and insight – week to June 6
By Barbara Obstoj-Cardwell. Editor
Regulatory news last week included US biotech Moderna receiving Food and Drug Administration (FDA) approval for its new COVID-19 Vaccine mNEXSPIKE. On the M&A front, French pharma major Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology pipeline. USA-based Cullinan Therapeutics has entered into a license deal with China’s Genrix Bio for the latter’s velinotamig for multiple myeloma. Also of note, RegeNXBio released what lookedlike good results for its investigational Duchenne muscular dystrophy drug RGX-202.
mNexspike approval comes in line; focus on Moderna’s ability to preserve BS
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze